Research ArticleFragile X Syndrome

Selective inhibition of glycogen synthase kinase 3α corrects pathophysiology in a mouse model of fragile X syndrome

See allHide authors and affiliations

Science Translational Medicine  20 May 2020:
Vol. 12, Issue 544, eaam8572
DOI: 10.1126/scitranslmed.aam8572

Log in to view full text

Log in through your institution

Log in through your institution

Stay Connected to Science Translational Medicine

Navigate This Article